Medical Complications of Obesity and Optimization of the Obese Patient for Colorectal Surgery

ABSTRACT

Obesity is a medical epidemic with an enormous impact on disease prevalence and health care utilization. In the preoperative period, an awareness of medical issues associated with obesity is an important part of the planning for surgical procedures. The authors highlight the diagnostic and treatment options for medical conditions commonly affecting the obese patient including diabetes, hypertension, coronary artery disease, and deep venous thrombosis.

KEYWORDS

Obesity - preoperative care - diabetes - hypertension - cardiovascular disease

REFERENCES

• 1 Centers for Disease Control .Vital signs. Available at: http://www.cdc.gov/VitalSigns/AdultObesity/index.html Accessed Noember 9, 2011
• 2 Thorpe K E, Florence C S, Howard D H, Joski P. The impact of obesity on rising medical spending.  Health Aff. 2004;  W4 480-486
• 3 US Department of Health and Human Services .The Surgeon General's call to action to prevent and decrease overweight and obesity 2001. Rockville, MD: Office of the Surgeon General. 2001. Available at: http://www.surgeongeneral.gov/topics/obesity/calltoaction/CalltoAction.pdf Accessed November 9, 2011
• 4 Herrera F A, Yanagawa J, Johnson A, Limmer K, Jackson N, Savu M K. The prevalence of obesity and postoperative complications in a Veterans Affairs Medical Center general surgery population.  Am Surg. 2007;  73 (10) 1009-1012
• 5 Mullen J T, Moorman D W, Davenport D L. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery.  Ann Surg. 2009;  250 (1) 166-172
• 6 Merkow R P, Bilimoria K Y, McCarter M D et al.. Effect of body mass index on short-term outcomes after colectomy for cancer.  J Am Coll Surg. 2009;  208 (1) 53-61
• 7 Dindo D, Muller M K, Weber M, Clavien P A. Obesity in general elective surgery.  Lancet. 2003;  361 (9374) 2032-2035
• 8 Flegal K M, Carroll M D, Ogden C L, Curtin L R. Prevalence and trends in obesity among US adults, 1999-2008.  JAMA. 2010;  303 (3) 235-241
• 9 Geiss L S, Pan L, Cadwell B, Gregg E W, Benjamin S M, Engelgau M M. Changes in incidence of diabetes in U.S. adults, 1997-2003.  Am J Prev Med. 2006;  30 (5) 371-377
• 10 Cowie C C, Rust K F, Ford E S et al.. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005–2006.  Diabetes Care. 2009;  32 (2) 287-294
• 11 Gavin L A. Perioperative management of the diabetic patient.  Endocrinol Metab Clin North Am. 1992;  21 (2) 457-475
• 12 Lauruschkat A H, Arnrich B, Albert A A et al.. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting.  Circulation. 2005;  112 (16) 2397-2402
• 13 U.S. Preventive Services Task Force . Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement.  Ann Intern Med. 2008;  148 (11) 846-854
• 14 American Diabetes Association . Standards of medical care in diabetes—2011.  Diabetes Care. 2011;  34 (Suppl 1) S11-S61
• 15 Gerstein H C, Miller M E, Byington R P Action to Control Cardiovascular Risk in Diabetes Study Group et al.. Effects of intensive glucose lowering therapy in type 2 diabetes.  N Engl J Med. 2008;  358 (24) 2545-2559
• 16 Sheehy A M, Gabbay R A. An overview of preoperative glucose evaluation, management and perioperative impact.  J Diabetes Sci Technol.  2009;  3 (6) 1261-1269
• 17 Rehman H U, Mohammed K. Perioperative management of diabetic patients.  Curr Surg. 2003;  60 (6) 607-611
• 18 Jacober S J, Sowers J R. An update on perioperative management of diabetes.  Arch Intern Med. 1999;  159 (20) 2405-2411
• 19 Salpeter S R, Greyber E, Pasternak G A, Salpeter E E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.  Cochrane Database Syst Rev. 2010;  (Issue 4) CD002967. 10.1002/14651858.CD002967.pub4
• 20 Bailey C J, Turner R C. Metformin.  N Engl J Med. 1996;  334 (9) 574-579
• 21 Dagogo-Jack S, Alberti KGMM. Management of diabetes mellitus in surgical patients.  Diabetes Spectrum. 2002;  15 44-48
• 22 Centers for Disease Control and Prevention (CDC) . Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008.  MMWR Morb Mortal Wkly Rep. 2011;  60 (4) 103-108
• 23 Kannel W B, Brand N, Skinner Jr J J, Dawber T R, McNamara P M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study.  Ann Intern Med. 1967;  67 (1) 48-59
• 24 Wilson P W, D'Agostino R B, Sullivan L, Parise H, Kannel W B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.  Arch Intern Med. 2002;  162 (16) 1867-1872
• 25 Huang Z, Willett W C, Manson J E et al.. Body weight, weight change, and risk for hypertension in women.  Ann Intern Med. 1998;  128 (2) 81-88
• 26 Calhoun D A, Jones D, Textor S et al.. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.  Hypertension. 2008;  51 (6) 1403-1419
• 27 Chobanian A V, Bakris G L, Black H R Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Hypertension. 2003;  42 (6) 1206-1252
• 28 Persell S D. Prevalence of resistant hypertension in the United States, 2003-2008.  Hypertension. 2011;  57 (6) 1076-1080
• 29 Bramlage P, Pittrow D, Wittchen H U et al.. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.  Am J Hypertens. 2004;  17 (10) 904-910
• 30 Hall J E. Pathophysiology of obesity hypertension.  Curr Hypertens Rep. 2000;  2 (2) 139-147
• 31 Coatmellec-Taglioni G, Ribière C. Factors that influence the risk of hypertension in obese individuals.  Curr Opin Nephrol Hypertens. 2003;  12 (3) 305-308
• 32 Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension.  Hypertension. 2006;  48 (5) 787-796
• 33 Rahmouni K, Correia M LG, Haynes W G, Mark A L. Obesity-associated hypertension: new insights into mechanisms.  Hypertension. 2005;  45 (1) 9-14
• 34 Haynes W G, Morgan D A, Walsh S A, Mark A L, Sivitz W I. Receptor-mediated regional sympathetic nerve activation by leptin.  J Clin Invest. 1997;  100 (2) 270-278
• 35 Satoh N, Ogawa Y, Katsuura G et al.. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion.  Diabetes. 1999;  48 (9) 1787-1793
• 36 Rahmouni K. Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity.  Curr Hypertens Rep. 2010;  6 (2) 104-209
• 37 Landesberg G, Einav S, Christopherson R et al.. Perioperative ischemia and cardiac complications in major vascular surgery: importance of the preoperative twelve-lead electrocardiogram.  J Vasc Surg. 1997;  26 (4) 570-578
• 38 Fleisher L A. Preoperative evaluation of the patient with hypertension.  JAMA. 2002;  287 (16) 2043-2046
• 39 Frohlich E D. Clinical management of the obese hypertensive patient.  Cardiol Rev. 2002;  10 (3) 127-138
• 40 Rosei E A, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies.  J Hypertens. 2006;  24 (12) 2482-2485
• 41 Eagle K A, Berger P B, Calkins H et al.. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).  Anesth Analg. 2002;  94 (5) 1052-1064
• 42 Weksler N, Klein M, Szendro G et al.. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery?.  J Clin Anesth. 2003;  15 (3) 179-183
• 43 Fleisher L A, Beckman J A, Brown K A ACC/AHA TASK FORCE MEMBERS et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.  Circulation. 2007;  116 (17) 1971-1996
• 44 The Trials of Hypertension Prevention Collaborative Research Group . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II.  Arch Intern Med. 1997;  157 (6) 657-667
• 45 Mikhail N, Golub M S, Tuck M L. Obesity and hypertension.  Prog Cardiovasc Dis. 1999;  42 (1) 39-58
• 46 Wofford M R, Smith G, Minor D S. The treatment of hypertension in obese patients.  Curr Hypertens Rep. 2008;  10 (2) 143-150
• 47 U.S. Department of Health and Human Services .How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010
• 48 Sharma A M, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?.  J Hypertens. 2001;  19 (4) 667-674
• 49 Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.  N Engl J Med. 1989;  321 (13) 868-873
• 50 Reisin E, Weir M R, Falkner B, Hutchinson H G, Anzalone D A, Tuck M L. Treatment in Obese Patients With Hypertension (TROPHY) Study Group . Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial.  Hypertension. 1997;  30 (1 Pt 1) 140-145
• 51 Gress T W, Nieto F J, Shahar E, Wofford M R, Brancati F L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.  N Engl J Med. 2000;  342 (13) 905-912
• 52 Reaven G M, Clinkingbeard C, Jeppesen J et al.. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.  Am J Hypertens. 1995;  8 (5 Pt 1) 461-466
• 53 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systemic analysis.  Hypertension. 2001;  37 (2) 250-254
• 54 UK Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.  BMJ. 1998;  317 (7160) 713-720
• 55 Davis B R, Oberman A, Blaufox M D The Trial of Antihypertensive Interventions and Management Research Group et al. Effect of antihypertensive therapy on weight loss.  Hypertension. 1992;  19 (4) 393-399
• 56 MacMahon S W, Macdonald G J, Bernstein L, Andrews G, Blacket R B. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients.  Lancet. 1985;  1 (8440) 1233-1236
• 57 Hansson L, Lindholm L H, Niskanen L et al.. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.  Lancet. 1999;  353 (9153) 611-616
• 58 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med. 2000;  342 (3) 145-153
• 59 Julius S, Kjeldsen S E, Weber M VALUE trial group et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.  Lancet. 2004;  363 (9426) 2022-2031
• 60 Lindholm L H, Ibsen H, Borch-Johnsen K LIFE study group et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study.  J Hypertens. 2002;  20 (9) 1879-1886
• 61 Rosenman D J, McDonald F S, Ebbert J O, Erwin P J, LaBella M, Montori V M. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period.  J Hosp Med. 2008;  3 (4) 319-325
• 62 Kheterpal S, Khodaparast O, Shanks A, O'Reilly M, Tremper K K. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.  J Cardiothorac Vasc Anesth. 2008;  22 (2) 180-186
• 63 Auron M, Harte B, Kumar A, Michota F. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.  Postgrad Med J. 2011;  87 (1029) 472-481
• 64 de Courten M, Ferrari P, Schneider M et al.. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.  Eur J Clin Pharmacol. 1993;  44 (5) 457-462
• 65 Hubert H B, Feinleib M, McNamara P M, Castelli W P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.  Circulation. 1983;  67 (5) 968-977
• 66 Rexrode K M, Carey V J, Hennekens C H et al.. Abdominal adiposity and coronary heart disease in women.  JAMA. 1998;  280 (21) 1843-1848
• 67 Yusuf S, Hawken S, Ounpuu S INTERHEART Study Investigators et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  Lancet. 2004;  364 (9438) 937-952
• 68 Wanahita N, Messerli F H, Bangalore S, Gami A S, Somers V K, Steinberg J S. Atrial fibrillation and obesity—results of a meta-analysis.  Am Heart J. 2008;  155 (2) 310-315
• 69 Poirier P, Giles T D, Bray G A American Heart Association et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement of Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.  Circulation. 2006;  113 (6) 898-918
• 70 Ramaswamy A, Gonzalez R, Smith C D. Extensive preoperative testing is not necessary in morbidly obese patients undergoing gastric bypass.  J Gastrointest Surg. 2004;  8 (2) 159-164, discussion 164–165
• 71 Reilly D F, McNeely M J, Doerner D et al.. Self-reported exercise tolerance and the risk of serious perioperative complications.  Arch Intern Med. 1999;  159 (18) 2185-2192
• 72 Lee T H, Marcantonio E R, Mangione C M et al.. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.  Circulation. 1999;  100 (10) 1043-1049
• 73 Devereaux P J, Yang H, Yusuf S POISE Study Group et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.  Lancet. 2008;  371 (9627) 1839-1847
• 74 Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli F H. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis.  Lancet. 2008;  372 (9654) 1962-1976
• 75 Dunkelgrun M, Boersma E, Schouten O Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).  Ann Surg. 2009;  249 (6) 921-926
• 76 McFalls E O, Ward H B, Moritz T E et al.. Coronary-artery revascularization before elective major vascular surgery.  N Engl J Med. 2004;  351 (27) 2795-2804
• 77 Fernandez Jr A Z, Demaria E J, Tichansky D S et al.. Multivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesity.  Ann Surg. 2004;  239 (5) 698-702, discussion 702–703
• 78 Scholten D J, Hoedema R M, Scholten S E. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery.  Obes Surg. 2002;  12 (1) 19-24
• 79 Shepherd M F, Rosborough T K, Schwartz M L. Heparin thromboprophylaxis in gastric bypass surgery.  Obes Surg. 2003;  13 (2) 249-253
• 80 Miller M T, Rovito P F. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery.  Obes Surg. 2004;  14 (6) 731-737
• 81 Cotter S A, Cantrell W, Fisher B, Shopnick R. Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery.  Obes Surg. 2005;  15 (9) 1316-1320
• 82 Wille-Jørgensen P, Rasmussen M S, Andersen B R, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery.  Cochrane Database Syst Rev. 2003;  (Issue 4) CD001217
• 83 Fleming F J, Kim M J, Salloum R M, Young K C, Monson J R. How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database.  Dis Colon Rectum. 2010;  53 (10) 1355-1360
• 84 Rasmussen M S, Jørgensen L N, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.  Cochrane Database Syst Rev. 2009;  (1, Issue 1) CD0052718 DOI: 10.1002/14651858.CD0052718.pub2
• 85 Schuster R, Hagedorn J C, Curet M J, Morton J M. Retrievable inferior vena cava filters may be safely applied in gastric bypass surgery.  Surg Endosc. 2007;  21 (12) 2277-2279